In partnership with leading healthcare institutions

Precision Health Economics analyzed the impact of population screening on health outcomes. The model finds that universal access to genetic testing for CDC Tier 1 genomic conditions with Color’s delivery model can cost-effectively help over 1 million U.S. adults prevent or detect cancer and heart disease earlier over a 20-year time horizon⁷.

U.S. adult lives positively affected through population screening for CDC Tier 1 genomic conditions

Hover over states to view estimated impact

Where cutting-edge genomics and software meets marketing excellence and user-centric design

Affordable, clinical-grade testing

Genetic testing for CDC Tier 1 genomic conditions, performed in our CAP-accredited and CLIA-certified lab

Effective patient recruitment

Patient recruitment support for population screening through user-friendly marketing, educational events, and online enrollment

Provider education

Clearly written materials to help providers understand and effectively counsel patients on test results and screening guidelines

Digital tools and ongoing engagement

Collaborative, online pedigree tools and ongoing updates on variant classifications and screening guidelines to inform follow-up care

Genetic counselors and cascade screening

Complimentary access to our genetic counselors and cascade screening through Color’s Family Testing Program

Implementation toolkit

Support for implementation research through study design templates, example IRBs, consent templates, pre/post survey questions, outcome metrics and more

For researchers interested in accelerating scientific discoveries

Color enables health systems to engage in large-scale genomic research

Logistics-free population research

Broad-based research on unselected, recontactable populations of average risk with full research workflows

Intuitive analytical tools

Best-in-class data analytics infrastructure to support large-scale genotype-phenotype research

Affordable genome sequencing

The most economically accessible whole exome or genome sequencing, performed in our CLIA-certified lab

“We are proud to deliver the most advanced cancer care and provide access to critical genetic information for all of our patients to help them create a personalized care plan. This exciting new partnership demonstrates our shared goal of opening up access to potentially life-saving genetic information and helping people lead healthier lives.”

-Karen E. Knudsen PhD, Director- NCI-Designated Sidney Kimmel Cancer Center, Thomas Jefferson University & Jefferson Health

1. Murray. ROR from Research Exomes. IGNITE Network Clinical Informatics Working Group. 2017.

2. CDC. Tier 1 Genomics Applications and their Importance to Public Health. Accessed May 2018.

3. Hampel & de la Chapelle. The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means? Cancer Prevention Research. 2011.

4. Nordestgaard et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal. 2013.

5. Plichta et al. What’s New in Genetic Testing for Cancer Susceptibility? Oncology Journal. 2016.

6. Drohan et al. Hereditary Breast and Ovarian Cancer and Other Hereditary Syndromes: Using Technology to Identify Carriers. Annals of Surgical Oncology. 2012.

7. According to a health outcomes study commissioned by Color and developed by an independent firm, Precision Health Economics, population screening for CDC Tier 1 genomic conditions over a 20-year time horizon is cost-effective compared to the current criteria-based approach.  A full summary of findings will be published shortly.